5:50 PM
Nov 01, 2007
 |  BC Extra  |  Company News

Neurocrine grants Dainippon indiplon rights for Japan

NBIX granted Dainippon Sumitomo (Tokyo:4506; Osaka:4506) exclusive rights to develop and commercialize indiplon in Japan. An NDA for the immediate-release formulation of the non-benzodiazepine GABA A receptor agonist is under FDA review with...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >